Stockreport

Edesa Biotech in-licenses two COVID-19 candidates; shares up 21% [Seeking Alpha]

Edesa Biotech, Inc. - Common Shares  (EDSA) 
PDF Thinly traded nano cap Edesa Biotech (EDSA+21.1%agreementThe monoclonal antibodies inhibit the signaling proteins TLR4 and CXCL10, respectively.Under the terms of the de [Read more]